VolitionRx Limited announced clinical study results showing its Nu.Q Vet Feline blood test accurately detects lymphoma in cats, the most common cancer affecting the species. The test achieved 100% specificity, meaning no false positives, while detecting more than 80% of feline lymphomas. This development supports creation of what the company expects to be the world's first simple and affordable liquid biopsy test for feline cancer.
The importance of this advancement lies in addressing a significant veterinary challenge. Feline cancer has historically been difficult to diagnose early, often requiring invasive biopsies or costly imaging procedures after symptoms have progressed. Veterinarians have sought a feline screening solution for years, and this blood-based assay could transform diagnostic approaches. Following the international rollout of its canine cancer test, VolitionRx has now demonstrated the technology's effectiveness in cats and plans to complete product development.
The potential impact extends beyond individual pet owners to the broader veterinary industry. Early detection through a simple blood test could lead to earlier intervention, potentially improving treatment outcomes and quality of life for affected cats. The company plans to make the Nu.Q Vet Feline Test available through existing distribution networks, including reference laboratories and point-of-care platforms, which could facilitate widespread adoption in veterinary practices.
This development represents progress in veterinary diagnostics that parallels advances in human medicine. Liquid biopsy technology, which detects disease markers in blood rather than requiring tissue samples, has shown promise in human oncology and is now being adapted for veterinary use. The successful application in both canines and felines suggests broader potential for the technology across species.
The company's multinational operations and epigenetics focus position it to advance veterinary diagnostics further. VolitionRx's research and development activities are centered in Belgium, with additional facilities in the U.S. and London. The company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. For further information about the company's broader efforts, visit https://volition.com/.
This announcement comes through BioMedWire, a specialized communications platform focusing on biotechnology and biomedical sciences developments. The platform is part of the Dynamic Brand Portfolio that delivers various communication solutions. For more information about this distribution channel, visit https://www.BioMedWire.com.
The implications of this development are substantial for veterinary medicine, potentially changing how feline lymphoma is detected and managed. As product development continues, this technology could establish new standards for non-invasive cancer screening in veterinary practice, benefiting both animal health and the veterinary diagnostics industry.
